WFH statement - EN

WFH General Assembly passes a declaration on WHO 2023 edition of the Lists of Essential Medicines

A motion was adopted at the World Federation of Hemophilia (WFH) 2024 Annual Meeting of the General Assembly, held on April 21 at the WFH 2024 World Congress, related to the inclusion of pathogen-reduced cryoprecipitate and cryoprecipitate in the 2023 edition of the World Health Organization’s (WHO) Essential Medicines List and Essential Medicines List for Children.

Also available in: Français Español

During the WFH 2024 Annual Meeting of the General Assembly, Brian O’Mahony, Chief Executive of the Irish Haemophilia Society national member organization (NMO) moved to pass the motion, which was then voted on and ratified.

Here is the text of the motion:

“That grave concern was expressed over the decision by the World Health Organization (WHO) to place pathogen reduced cryoprecipitate and cryoprecipitate on the core Essential Medicines List, with safe and effective clotting factor concentrates relegated to the complementary medicines list. This will lead to morbidity and mortality. The General Assembly calls on the WHO to reverse this erroneous decision without further delay.”

To read “WFH statement: inclusion of cryoprecipitate in the WHO’s EML and EMLc” published in December 2023, please click here.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.